share_log

Aequus Announces Zimed PF Now Available in Canada

Aequus Announces Zimed PF Now Available in Canada

Aequus 宣佈 Zimed PF 現已在加拿大上市
GlobeNewswire ·  2023/08/24 20:00

VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) ("Aequus" or the "Company"), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.

不列顛哥倫比亞省溫哥華,2023年8月24日(GLOBE NEWSWIRE)——今天宣佈的特種製藥公司Aequs Pharmicals Inc.(多倫多證券交易所股票代碼:AQS,OTCQB:AQSZ)(“Aequus” 或 “公司”),我們很高興地宣佈成立 Zimed PF,加拿大首款用於青光眼患者的不含防腐劑的多劑量比馬前列素。

"This marks a new growth phase for Aequus and the launch of a Preservative Free (PF) innovation that brings value to both physicians and patients in a large therapeutic eye category," says Grant Larsen, Chief Commercial Officer for Aequus Pharmaceuticals Inc. Canada. "An exciting product innovation, launched in multiple countries around the world, this product will be available at pharmacies across Canada in the coming weeks."

加拿大Aequs Pharmicals Inc.首席商務官格蘭特·拉森說:“這標誌着Aequus進入了一個新的增長階段,也標誌着一項無防腐劑(PF)創新的推出,該創新爲大型治療性眼科類別的醫生和患者帶來了價值。”“該產品是一項激動人心的產品創新,已在全球多個國家推出,將在未來幾周內在加拿大各地的藥店上市。”

For more information, please visit and join us in celebrating this milestone in glaucoma treatment.

欲了解更多信息,請訪問 並和我們一起慶祝青光眼治療的這一里程碑。

About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus, founded in 2015, has successfully grown multiple products and brands in strategic therapeutic areas including Ophthalmology, Optometry, Transplant and Rare Disease. Aequus plans to build on its Canadian commercial platform through the application of sales, marketing and expert knowledge of the Canadian marketplace utilizing internal development, acquisition, or licenses with preferred strategic partners. For further information, please visit .

關於 Aequs 製藥
Aequs Pharmicals Inc.(多倫多證券交易所: AQS,OTCQB: AQSZF) 是一家成長中的專業製藥公司,專注於開發和商業化高品質、差異化產品。Aequs 成立於 2015 年,在眼科、驗光、移植和罕見病等戰略治療領域成功發展了多種產品和品牌。Aequus計劃利用內部開發、收購或與首選戰略合作伙伴簽訂的許可,通過應用銷售、營銷和加拿大市場的專業知識,在其加拿大商業平台上再接再厲。欲了解更多信息,請訪問 。

About Glaucoma, Dry Eye and Zimed PF
Zimed PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Glaucoma and elevated intraocular pressure can cause vision loss or blindness by damaging the optic nerve located at the back of the eye. Dry eye disease is often associated with glaucoma due to factors including age, environment, allergies, and preservatives in eyedrops. Zimed PF is the first preservative-free, multi-dose bottle bimatoprost available in Canada. Zimed PF (bimatoprost 0.03%) received market authorization from Health Canada in December 2022.

關於青光眼、乾眼症和 Zimed PF
Zimed PF 適用於降低開角型青光眼或高眼壓患者的眼壓升高 (IOP)。青光眼和眼壓升高會損害位於眼後的視神經,從而導致視力下降或失明。由於年齡、環境、過敏和眼藥水中的防腐劑等因素,乾眼病通常與青光眼有關。Zimed PF 是加拿大第一款不含防腐劑的多劑量瓶裝比馬前列素。 Zimed PF(比馬前列素 0.03%) 2022 年 12 月獲得加拿大衛生部的市場許可。

Forward-Looking Statements:
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; successful product launches; the Company's expected revenues; the regulatory approval of its products; the Company's ability to attract international partners; and ongoing discussions with and the Company's ability to secure potential partners to further grow our product portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company's ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company's current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company's ability to attract and retain skilled staff; market competition; the products and technology offered by the Company's competitors; the impact of the coronavirus (COVID-19) on the Company's operations; and the Company's ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading "Risk Factors" in the Company's Annual Information Form dated May 1, 2023, a copy of which is available on Aequus' profile on the SEDAR website at www sedarplus.ca, and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

前瞻性陳述:
本新聞稿可能包含適用的加拿大證券立法規定的前瞻性陳述或前瞻性信息,這些陳述可能不是基於歷史事實,包括但不限於包含 “相信”、“可能”、“計劃”、“將”、“估計”、“繼續”、“預期”、“打算”、“預期”、“預期”、“預期”、“預期”、“預期”、“預期”、“預期”、“預期”、“預期”、“預期”、“預期”、“可能” 等詞語的陳述。前瞻性陳述必須基於我們根據我們的經驗和對歷史趨勢、當前狀況和預期未來發展的看法,以及我們認爲適當的因素所做的估計和假設。前瞻性陳述包括但不限於以下方面的陳述:我們的商業模式和戰略計劃的實施;未來的收入增長趨勢;產品的成功發佈;公司的預期收入;監管部門對其產品的批准;公司吸引國際合作夥伴的能力;以及正在進行的討論 以及公司尋找潛在合作伙伴以進一步擴大我們的產品組合的能力。此類陳述反映了我們當前對未來事件的看法,受風險和不確定性的影響,並且必須基於許多估計和假設,儘管Aequus認爲這些估計和假設是合理的,但本質上會受到重大的商業、經濟、競爭、政治和社會不確定性和突發事件的影響。許多因素都可能導致我們的實際業績、業績或成就與此類前瞻性陳述可能表達或暗示的任何未來業績、業績或成就存在重大差異。在發表本新聞稿中包含的前瞻性陳述時,公司做出了各種重大假設,包括但不限於:獲得監管部門的批准;總體業務和經濟狀況;公司成功發放許可或銷售其現有產品以及獲得許可和開發新產品的能力;假設公司目前與第三方的良好關係將得到維持;以合理條件獲得融資;公司吸引和留住熟練員工的能力;市場競爭;公司競爭對手提供的產品和技術;冠狀病毒(COVID-19)對公司運營的影響;以及公司保護專利和所有權的能力。在評估前瞻性陳述時,當前和潛在股東應特別考慮本文以及公司2023年5月1日年度信息表中 “風險因素” 標題下列出的各種因素,該表的副本可在SEDAR網站上的Aequus個人資料中查閱,網址爲www sedarplus.ca,正如Aequus的SEDAR個人資料中不時披露的那樣。如果其中一個或多個風險或不確定性,或者我們目前不知道的風險成爲現實,或者如果這些前瞻性陳述所依據的假設被證明不正確,則實際結果可能與本文所述的結果存在重大差異。這些前瞻性陳述自本新聞稿發佈之日起作出,除非適用的證券法要求,否則我們不打算也不承擔任何義務更新這些前瞻性陳述。投資者請注意,前瞻性陳述並不能保證未來的表現,本質上是不確定的。因此,提醒投資者不要過分依賴前瞻性陳述。

On behalf of the Board of Directors,

代表董事會,

"Douglas Janzen"
Director & CEO

“道格拉斯·詹森”
董事兼首席執行官

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this news release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Contact Information:
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906

聯繫信息:
Aequus 投資者關係
電子郵件:investors@aequuspharma.ca
電話:604-336-7906


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論